SCHEMBL3539723

SCHEMBL3539723

CC(=O)N1CCN(c2ccc(N)c(N3CCC(C)CC3)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 4/20 0.55
CSF1R P07333 3/20 0.55
GAA P10253 4/20 0.54
MAPT P10636 4/20 0.54
KDM4E B2RXH2 3/20 0.54
MAPK1 P28482 2/20 0.54
HTT P42858 2/20 0.54
CASP6 P55212 1/20 0.54
GFER P55789 1/20 0.54
RECQL P46063 1/20 0.54
PTK2B Q14289 1/20 0.54
GPR174 Q9BXC1 1/20 0.49
POLB P06746 1/20 0.49
NR4A1 P22736 1/20 0.49
HSD17B10 Q99714 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 1/20 0.49
S100B P04271 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27691384 0.90 LGMN (0.55) LGMNCSF1RGAAMAPTKDM4E
SCHEMBL3539721 0.85 CSF1R (0.51) CSF1RGAAMAPTKDM4ECASP6
SCHEMBL3541321 0.84 GPR119 (0.53) LGMNGAAMAPTKDM4EMAPK1
SCHEMBL31000463 0.84 GPR119 (0.53) LGMNGAAMAPTKDM4EMAPK1
SCHEMBL3538623 0.82 GAA (0.79) LGMNCSF1RGAAMAPTKDM4E
SCHEMBL3541924 0.81 CSF1R (0.57) LGMNCSF1RGAAMAPTKDM4E
SCHEMBL3537508 0.80 CSF1R (0.55) LGMNCSF1RGAAMAPTKDM4E
SCHEMBL23123959 0.79 GFER (0.68) GAAMAPTKDM4EMAPK1HTT
SCHEMBL3958578 0.79 GAA (0.55) LGMNCSF1RGAAMAPTKDM4E
SCHEMBL3540354 0.79 LGMN (0.77) LGMNCSF1RGAAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP claimed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US claimed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES LGMN 3741/4885CSF1R 34/4885GAA 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.